Health TrialsbyHealthPanel

Comparative Study Between Intrathecal Magnesium Sulfate, Neostigmine and Fentanyl as Adjuvant for Bubivacaine in Postoperative Analgesia in Lower Abdominal Surgeries

ConditionsMagnesium SulfateNeostigmineFentanyl
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-55
SponsorAssiut University

About this trial

Lower abdominal surgeries often result in severe pain, which in turn can cause rapid and shallow breathing, retention of secretions and poor patient compliance. Justifiably, apart from the fear for the surgery outcome, patients are concerned mainly with postoperative pain. If treated inadequately, acute pain can have serious consequences for patient health mainly with postoperative complications, prolonged recovery and increased length of hospital stay. Higher levels of postoperative pain and pain distress are associated with increased morbidity, poorer functional recovery, and reduced quality of life.

Aim of the study To compare the duration, quality of analgesia, and side effects between intrathecal Magnesium sulfate, neostigmine and fentanyl as adjuvant for bubivacaine as postoperative analgesia in lower abdominal surgeries

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

• the American Society of Anesthesiologists (ASA) classification I-II

Age >18 up to 55 years old

Both sex

Patients who will undergo lower abdominal surgeries

Disqualifiers

• Patients' refusal.

Patients with morbid obesity, cardiac diseases, hepatic diseases, renal diseases, diabetes mellitus with polyneuritis.

Patients who were in risk-scoring groups American Society of Anesthesia III-IV.

Hypertensive patients receiving therapy with adrenergic receptor antagonist, calcium channel blocker and/or angiotensin converting enzyme inhibitor.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Magnesium Sulfate and Bupivacaine 0.125%

    Drug

    patients will receive 15 mg of 0.5% hyperbaric bupivacaine + 50 mg Magnesium sulfate intrathecally.

  • bupivacaine and Neostigmine

    Drug

    patients will receive 15mg of 0.5% hyperbaric bupivacaine + 50 µg Neostigmine intrathecally

  • fentanyl and bupivacaine

    Drug

    patients will receive 15mg of 0.5% hyperbaric bupivacaine + 25µg of fentanyl intrathecally.

Treatment groups

66 Participants
are divided into 3 treatment groups
Group A: group 1Experimental treatment 1 intervention
Group B: group 2Experimental treatment 1 intervention
Group C: group3Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

first request of rescue analgesia

The time of first request of rescue analgesia calculated from the time of spinal anesthesia.

Time frame
baseline

Secondary outcomes

1

post operative VAS score

post operative VAS score

Time frame
baseline

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: